254 results on '"Yoneshima, Yasuto"'
Search Results
2. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase
3. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
4. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
5. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
6. Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors
7. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial
8. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
9. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
10. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers
11. Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment
12. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
13. Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review
14. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
15. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
16. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
17. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors
18. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
19. A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy
20. Successful Treatment against Mediastinal Methicillin-resistant Staphylococcus aureus Infection after an Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Procedure
21. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells
22. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
23. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis
24. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
25. Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer
26. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFRactivating mutations
27. MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
28. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
29. Patient-oriented optimal depth of conscious sedation using midazolam during flexible bronchoscopy: A prospective open-labeled single-arm trial
30. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers
31. Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β
32. Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
33. Afatinib-Induced Bronchiolitis Obliterans
34. Pleuroparenchymal fibroelastosis secondary to autologous peripheral blood stem cell transplantation: A case report
35. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
36. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
37. MicroRNA-326 Negatively Regulates CD155 Expression in Lung Adenocarcinoma
38. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
39. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
40. P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan
41. Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
42. Additional file 1 of A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
43. Additional file 2 of A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
44. Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
45. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.
46. Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement
47. Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
48. Abstract 1918: Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM-1 receptor
49. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12Cmutation: a randomised, open-label, phase 3 trial
50. Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.